Table 3.
Eligibility criteria.
| Inclusion criteria | Exclusion criteria |
|---|---|
| Histological diagnosis of invasive breast carcinoma | Metastatic disease |
| ER > 50% | Inflammatory breast carcinoma |
| PR > 20% | Impossibility of treatments due to comorbidities |
| Ki67 ≤ 35% | Hemoglobin <7.0 g ∕dL |
| Tumor ≧ 2 cm using US | AP ≥ 1.5 times the reference value |
| Tumor <2 cm using US with impaired lymph nodea | Neutrophil count <1500 U ∕mm3 |
| Platelet count <100,000 U ∕μL | |
| Serum creatinine> 1.5 mg∕dL | |
| Score >2 on the ECOG Scale | |
| Ongoing pregnancy |
ER: Estrogen receptor; PR: Progesterone receptor; US: Ultrasonography; AP: Alkaline phosphatase; ECOG: Eastern Cooperative Oncology Group.
a
Metastatic involvement should be defined by cytology (US-guided fine needle aspiration (FNA) of the suspected lymph node) or histology (core biopsy of the suspected lymph node or biopsy of the sentinel lymph node before neoadjuvant therapy).